Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Table 1 Demographic and clinical characteristics according to clinical diagnosis prior to [¹⁸F]flutemetamol PET

Pre-PET etiology	AD (n = 144)	FTD (n = 28)	OD (n = 19)	NN (n = 20)
Age (years)	62 ± 6 (45–70)	62 ± 5 (52–69)	63 ± 6 (48–69)	60 ± 5 (49–69)
Gender, female	71 (49%)	13 (46%)	7 (37%)	4 (20%)
MMSE	23 ± 3	25 ± 3	24 ± 4	24 ± 4
CDR (0.5/1.0/2.0)	77/50/6	18/9/1	8/9/0	13/4/1
APOE genotype, e4 carrier	87 (67%)	7 (28%)^a	10 (63%)	14 (78%)
Specified diagnosis	6 lv-PPA 138 AD	20 bvFTD 2 SD 6 PNFA	3 VaD 7 DLB 5 CBD 4 PSP	12 psychiatry 3 CTE 2 meningeoma 1 PTSS 1 OSAS 1 limbic encephalitis

Data are presented as mean ± SD (range), n (%), or mean ± SD unless stated otherwise. Differences between groups were assessed using ANOVA with post-hoc Bonferroni tests (age and MMSE), χ² tests (gender, APOE genotype), and Kruskal–Wallis with post-hoc Mann–Whitney U tests (CDR)
^aFTD < other diagnostic groups; P < 0.05
PET positron emission tomography, MMSE Mini Mental State Examination, CDR clinical dementia rating. AD Alzheimer’s disease dementia, lv-PPA logopenic-variant primary progressive aphasia, FTD frontotemporal dementia, bvFTD behavioral variant FTD, SD semantic dementia, PNFA, primary nonfluent aphasia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis, VaD vascular dementia DLB dementia with Lewy bodies, CBD corticobasal degeneration, PSP progressive supranuclear palsy, CTE chronic traumatic encephalopathy, PTSS posttraumatic stress syndrome, OSAS obstructive sleep apnea syndrome

ISSN: 1758-9193